Clinical trial · Expanded Access
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
NCT03906357CI-TRIAL-00057882no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Expanded access of Pemigatinib to treat a single patient with metastatic pancreatic cancer.
Conditions
Conditions (0)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Data not yet available
No condition recorded.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pemigatinib | Drug | Pemigatinib | ALIAS |
Eligibility
Eligibility (as posted)
Show eligibility criteria text
Inclusion Criteria: \- Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.